B细胞清除预防需糖皮质激素治疗的慢性移植物抗宿主病的随机安慰剂对照试验
一项随机、安慰剂对照、盲法试验比较奥比妥珠单抗(移植后第90、180、270、365天各1000mg)与安慰剂在cGVHD高危受者中的预防效果。
要点
- 奥比妥珠单抗预防性B细胞清除可显著降低1年需激素cGVHD发生率。
- 2年无免疫抑制无复发生存率在奥比妥珠单抗组更高。
- 中性粒细胞减少更常见,但非复发死亡率两组无差异。
核心结论
- 在cGVHD高危的同种异体移植受者中,早期B细胞清除显著降低需糖皮质激素cGVHD的发生率。
研究设计与样本
- 随机、安慰剂对照、盲法试验,比较奥比妥珠单抗1000mg(移植后第90、180、270、365天各一次)与安慰剂。
- 主要终点为1年需糖皮质激素cGVHD发生率。
主要发现
- 中性粒细胞减少在奥比妥珠单抗组更常见,但非复发死亡率两组无差异。
- 研究干预时无预存H-Y抗体的参与者中,奥比妥珠单抗组12个月需激素cGVHD发生率为8.6%,有H-Y抗体者为40%,安慰剂组有抗体者为41%、无抗体者为57%。
关键数值与推荐
- 奥比妥珠单抗剂量为1000mg,移植后第90、180、270、365天各一次。
临床怎么用
- 对于cGVHD高危的同种异体移植受者,可考虑预防性B细胞清除以降低需激素cGVHD风险。
- 使用奥比妥珠单抗预防时需关注中性粒细胞减少,但非复发死亡率未见增加。
- 预存H-Y抗体状态可能影响预防效果,无预存抗体者获益更明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chronic graft-versus-host disease (cGVHD) is a multisystem alloimmune disorder associated with abnormal B-cell biology and aberrant antibody responses. As B-cell-directed therapy can effectively treat established cGVHD, we tested whether prophylactic B-cell depletion could prevent the development of corticosteroid-requiring cGVHD following allogeneic transplantation. METHODS: We performed a randomized, placebo-controlled, and blinded trial comparing four doses of the B-cell-depleting antibody obinutuzumab (1,000 mg once on days 90, 180, 270, and 365 after transplantation) with placebo in transplant recipients receiving tacrolimus-based GVHD prevention at higher risk of cGVHD. The primary end point was the 1-year incidence of corticosteroid-requiring cGVHD. We measured antibody responses against Y chromosome-encoded minor histocompatibility (H-Y) antigens and correlated their occurrence with corticosteroid-requiring cGVHD incidence. RESULTS: One hundred seventy-eight participants were analyzed. The prophylactic administration of obinutuzumab resulted in profound B-cell depletion, a significant reduction in the incidence of steroid-requiring cGVHD at 1 year (13.3% v 35.2%; P = .0005), and an improvement in immunosuppression-free, relapse-free survival (48% v 34% at 2 years; P = .02). Neutropenia was more common in the obinutuzumab arm, but nonrelapse mortality was not different. In participants without preformed H-Y antibodies at the time of study intervention, obinutuzumab resulted in the most significant reduction in steroid-requiring cGVHD at 12 months (8.6%) compared with obinutuzumab participants with H-Y antibodies (40%) or placebo participants regardless of antibody status (41% with antibodies, 57% without antibodies). CONCLUSION: In allogeneic transplant recipients at higher risk of cGVHD, early B-cell depletion results in a significant reduction in the incidence of corticosteroid-requiring cGVHD.
引用
- Cutler C, Kim HT, El Banna H, et al. Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease. J Clin Oncol. 2026. PMID: 42060875. doi:10.1200/JCO-25-03104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。